Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer

June 13th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Cohen Discusses Surgery in Early-Stage Ovarian Cancer

June 12th 2018

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses surgery in patients with early-stage ovarian cancer.

Dr. O'Malley on the FORWARD II Phase Ib Study in Ovarian Cancer

June 12th 2018

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses the safety and efficacy results of the FORWARD II phase Ib study in patients with ovarian cancer.

Dr. Konecny Discusses the Role of PARP Inhibitors in Ovarian Cancer

June 7th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Glaspy on Immunogenicity in Ovarian Cancer

June 6th 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.

Dr. Rao on Improving Methods of Early Detection of Ovarian Cancer

June 6th 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.

Dr. Bansal on Chemotherapeutic Approaches for Patients With Ovarian Cancer

June 4th 2018

Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

Dr. Pietras on Palliative Care for Patients With Ovarian Cancer

June 1st 2018

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.

Dr. Krakow on Genetic Testing in Ovarian Cancer

May 30th 2018

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

Dr. McCann on Combination Trials With PARP Inhibitors in Ovarian Cancer

May 30th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses combination clinical trials of PARP inhibitors in patients with ovarian cancer.

Dr. Memarzadeh on p53 Reactivation in Ovarian Cancer

May 29th 2018

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

Dr. Konecny on the Use of PARP Inhibitors in Patients With Ovarian Cancer

May 29th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Essel Discusses Adverse Events of Bevacizumab in Ovarian Cancer

May 25th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events with bevacizumab (Avastin) in ovarian cancer.

Dr. Slamon on PARP Inhibitors in Ovarian Cancer

May 25th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Cohen on the Evolution of Surgery in Ovarian Cancer

May 25th 2018

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses the evolution of surgery in the treatment of patients with ovarian cancer.

Dr. Monk on the FORWARD I Trial in Ovarian Cancer

May 24th 2018

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FORWARD I trial in ovarian cancer.

Dr. Wingo Discusses Neoadjuvant Chemotherapy in Ovarian Cancer

May 17th 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the use of neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Wingo Weighs in on Surgical Approaches in Ovarian Cancer

May 15th 2018

Shana Wingo, MD, discusses the surgical landscape in patients with newly diagnosed ovarian cancer.

Treatment Approaches Evolving in Recurrent Ovarian Cancer

May 14th 2018

Dennis R. Scribner Jr, MD, discusses the elements and evolution of treatment for patients with recurrent ovarian cancer.

Genetic Testing Becoming More Widespread in Ovarian Cancer, But Challenges Remain

May 12th 2018

Mike Janicek, MD, discusses the importance of genetic testing and how the ovarian field can benefit from a better understanding of it through genetic counselors and self-education.